A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Conditions:   Breast Cancer;   Triple Negative Breast Cancer Interventions:   Drug: Carelizumab;   Drug: Nab-paclitaxel;   Drug: Apatinib Sponsor:   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials